AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01644773
Drug: Crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Starting dose level:~* Initial Treatment Plan: 130 mg/m\^2 per dose~* Modified Treatment Plan per Amendment 1.0: 165 mg/m\^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): once a day for 28 days~Cycles 2-26 (28 days each): once a day
Trial: NCT01644773
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Starting dose level: 50 mg/m\^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): starting on day 3, once a day for 28 days~Cycles 2-26 (28 days each): once a day
Trial: NCT02442713
Drug: fluvoxamine
RxNorm normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fluvoxamine: 50-300mg/day
Trial: NCT01996085
Drug: lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Angiotensin converting enzyme inhibitor recommended in case of:~1. hyperconstrictive profile (SVRI \> 2500-2800 dyn•s•cm-5•m2)~2. hyperdynamic profile (CI \> 4.2 l/min/m2 and/or HR \> 80/min) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with nebivolol)~3. hypervolemic profile (man - TFC \> 34 1/kOhm; women - TFC \> 24 1/kOhm) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with diuretic)~4. balanced profile
Trial: NCT01996085
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor blocker recommended in terms as for lisinopril in case of its intolerance (e.i. cough)
Trial: NCT01996085
Drug: Nebivolol
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beta-blocker recommended in case of:~1.hyperdynamic profile (CI \> 4.2 l/min/m2 and/or HR \> 80/min)
Trial: NCT01996085
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1/ SVRI \> 2800 dyn•s•cm-5•m2 (in combination with lisinopril/telmisartan)
Trial: NCT01996085
Drug: lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug choice at the discretion of physician (blinded to ICG)
Trial: NCT01996085
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor blocker recommended as for lisinopril in case of its intolerance (e.i. cough)
Trial: NCT01996085
Drug: Nebivolol
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug choice at the discretion of physician (blinded to ICG)
Trial: NCT01996085
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug choice at the discretion of physician (blinded to ICG)
Trial: NCT02720406
Drug: Intravenous ketamine0.5mg/kg
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine 0.5mg/kg after anesthesia and before surgery.
Trial: NCT02720406
Drug: Nebulized Ketamine 1mg/kg
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized Ketamine 1mg/kg given by nebulizer before anesthesia.
Trial: NCT02720406
Drug: Nebulized Ketamine 2mg/kg
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized Ketamine 2mg/kg given by nebulizer before anesthesia.
Trial: NCT01270087
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 40 mg IV every 14 days
Trial: NCT00145002
Drug: VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00145002
Drug: biweekly-CHOP with G-CSF and intrathecal prophylaxis
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04182672
Drug: FX006
RxNorm normalized name: Triamcinolone Acetonide Extended-Release
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be injected with the 5mL of FX006. This injection may be followed with up to 3mL of ropivacaine (depending on the capacity of the bursa), under ultrasound guidance.
Trial: NCT01971385
Drug: Squaric Acid solution
DrugBank: Squaric acid dibutyl ester (DB12223)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01810718
Drug: nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maximum tolerated dosage (MTD) will be defined in Phase I. First 3 patients (pts) will receive Nilotinib 200mg daily dose. If no dose limiting toxicities after at least 1month the next 3 pts will be treated with 300mg. If are\>=2 dose limiting toxicities the Phase I will end and MTD will be defined as the next lower dosage. If they will observe 1dose limiting toxicities, they will treat other 3 pts (same dosage); if there isn't dose limiting toxicity, they will increase the dosage in the next cohort; but if they will observe another dose limiting toxicity (tot limiting toxicities 2/6 pts), the study will continue using the previous dose. MTD will be considered the maximum dosage used to treat 6 pts achieving at most 1 dose limiting toxicities, or the previous dosage if with this dosage they we will achieve 2 dose limiting toxicities. Doses will not be escalated beyond \>600 or \<200mg/die The MTD will be used for phase II
Trial: NCT00387491
Drug: MOA-728
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00332228
Drug: depot naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: long-acting depot parenteral formulation of naltrexone
Trial: NCT00332228
Drug: BNT
RxNorm normalized name: BNT111
DrugBank: BNT111 (DB18177)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: behavioral therapy with oral naltrexone maintenance for the treatment of heroin addiction
Trial: NCT01088399
Drug: Somatropin (rDNA origin)
RxNorm normalized name: Somatropin (rDNA origin)
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose, frequency and duration are at discretion of attending physician, and determined on an individual basis.
Trial: NCT02397057
Drug: Injectafer
RxNorm normalized name: Injectafer
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01546688
Drug: Zonisamide at targeted daily doses of 100-500 mg/day
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Each group received 2 doses a day (in the morning and evening) during the Titration Period, once a day (in the evening) or BID during the Maintenance Phase, comprising 25 mg, 50 mg, or 100 mg of ZNS capsules
Trial: NCT01178203
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tab, 100mg in 6, 12 and 24 hours after root canal treatment
Trial: NCT01178203
Drug: Novafen
RxNorm normalized name: Novaferon
DrugBank: Novaferon (DB16483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg in 6, 12 and 24 hours after root canal treatment
Trial: NCT03120715
Drug: estrogen
RxNorm normalized name: Estrogen
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is \<7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is \>9 mm.
Trial: NCT03120715
Drug: hCG
RxNorm normalized name: HCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.
Trial: NCT03120715
Drug: progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
Trial: NCT03543137
Drug: Nicotine Prototype Mini lozenge
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of a prototype nicotine 4mg lozenge will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
Trial: NCT01366287
Drug: PF-03882845
RxNorm normalized name: PF-03882845
DrugBank: PF-03882845 (DB11814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of PF-03882845 suspension (75% SDD) will be given as a single oral dose under fasted condition
Trial: NCT01366287
Drug: PF-03882845
RxNorm normalized name: PF-03882845
DrugBank: PF-03882845 (DB11814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fasted condition
Trial: NCT01366287
Drug: PF-03882845
RxNorm normalized name: PF-03882845
DrugBank: PF-03882845 (DB11814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fed condition
Trial: NCT04027322
Drug: Budesonide 0.25 MG/ML Inhalant Solution
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Both medications used for the intervention groups are Glucocorticoids. The effect of glucocorticoids in AP can be attributed to their anti-inflammatory actions. They inhabit the formation of the pro-inflammatory mediators in the endothelial cells of the airways. This will decreases the inflammatory reaction at the pharynges which result in a reduction of throat pain.~Studies have shown that the use of a single dose of systemic glucocorticoids for acute pharyngitis did not result in significant adverse events and no serious adverse events were reported (7) (8).
Trial: NCT00699686
Drug: Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily bedtime subcutaneous insulin Glargine in individualized doses.
Trial: NCT04027322
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both medications used for the intervention groups are Glucocorticoids. The effect of glucocorticoids in AP can be attributed to their anti-inflammatory actions. They inhabit the formation of the pro-inflammatory mediators in the endothelial cells of the airways. This will decreases the inflammatory reaction at the pharynges which result in a reduction of throat pain.~Studies have shown that the use of a single dose of systemic glucocorticoids for acute pharyngitis did not result in significant adverse events and no serious adverse events were reported (7) (8).
Trial: NCT00699686
Drug: Detemir
RxNorm normalized name: Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daily bedtime subcutaneous insulin Detemir in individualized doses.
Trial: NCT03780790
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: % 0,25
Trial: NCT00349778
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg etoposide as 5 mL solution in clear ampules for injection.
Trial: NCT00349778
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan as single-use glass vials of freeze-dried melphalan hydrochloride (equivalent to 50 mg of melphalan), to be reconstituted in 0.9% sodium chloride solution to not greater than 0.45 mg/mL, and administered within 1 hour of constitution.
Trial: NCT00349778
Drug: Carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carmustine as a powder for reconstitution in 100 mg vials, to be reconstituted with 3 mL sterile dehydrated ethanol and D5W. Carmustine should be dissolved in 500 mL of 5% dextrose in water (D5W) and infused IV over 2 hours.
Trial: NCT00349778
Drug: Filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgrastim in vials of 300 µg or 480 µg at a concentration of 300 µg/mL, to be given as a daily subcutaneous injection.
Trial: NCT01775605
Drug: Synera
RxNorm normalized name: Synera
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synera Pain Patch
Trial: NCT03311789
Drug: PD-1 inhibitor + Gemcitabine + Cisplatin
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine: 1000mg/m2 on day 1 and 5 every 3 weeks. Cisplatin: 75mg/m2 on day 1 every 3 weeks. PD-1 inhibitor: Nivolumab 3mg/kg, or SHR-1210 200mg.
Trial: NCT00480246
Drug: BL 1020
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00480246
Drug: Perphenazine
RxNorm normalized name: Perphenazine
DrugBank: Perphenazine (DB00850)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04624490
Drug: Hyperpolarized Xe129
RxNorm normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During MRI scanning, subject will inhale hyperpolarized xenon gas for a maximum of 16 seconds per scan, with a maximum of 4 MR scans + Calibration in a given imaging session.
Trial: NCT04307082
Drug: [14C]-Ibrexafungerp
DrugBank: Ibrexafungerp (DB12471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radio-labeled Ibrexafungerp, single dose.
Trial: NCT01822977
Drug: omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00639626
Drug: insulin detemir [rDNA origin] injection
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Starting dose of 0.1-0.3 units/kg/day in a once daily subcutaneous injection.
Trial: NCT03484520
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tablet, oral
Trial: NCT03484520
Drug: Dinaciclib
RxNorm normalized name: Dinaciclib
DrugBank: Dinaciclib (DB12021)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous
Trial: NCT01605110
Drug: Hyperbaric oxygen treatment
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of 100% oxygen at 2.0 atmospheres absolute (ATA) inside mono-place chambers for 90 minutes (at depth).
Trial: NCT03209011
Drug: Peginterferon Alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
Trial: NCT01605110
Drug: Air sham
RxNorm normalized name: Herbal Essences Argan Oil Repair Shampoo
DrugBank: Argan oil (DB14310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of medical grade air (21%oxygen; sham) at 1.2 ATA inside mono-place chambers for 90 minutes.
Trial: NCT00277108
Drug: Escitalopram (Lexapro)
RxNorm normalized name: escitalopram Oral Tablet [Lexapro]
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00367835
Drug: SPD503 (Guanfacine hydrochloride)
RxNorm normalized name: Guanfacine Hydrochloride
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will start at 1mg tablet each morning and will subsequently be titrated (in 1 mg weekly increments) to optimal dose based upon tolerance and response to investigational product (not to exceed 4 mg/day).
Trial: NCT01640444
Drug: FOLFIRI + bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Bevacizumab 5 mg/kg iv, followed by~* Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~* Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~* 5-FU 400 mg/m2 iv bolus, followed by~* 5-FU 2,400 mg/m2 for 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle).
Trial: NCT01640444
Drug: FOLFIRI + cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Cetuximab in an initial 120-minute infusion on day 1 of 400 mg/m2, followed by 60-minute infusions of cetuximab at a dose of 250 mg/m2, once weekly~* FOLFIRI:~  * Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~ * Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~ * 5-FU 400 mg/m2 iv bolus, followed by~ * 5-FU 2,400 mg/m2 for 46 h continuous infusion FOLFIRI will be given after the cetuximab infusion on day 1 of each period (every 2 weeks: 1 cycle).
Trial: NCT01372410
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mcg once daily
Trial: NCT02311998
Drug: Bosutinib
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04496063
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous induction (6mg/kg) followed by Ustekinumab subcutaneous 90mg every 8 weeks
Trial: NCT01560689
Drug: Budesonide/formoterol
RxNorm normalized name: BUDESONIDE/FORMOTEROL
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 800 µg/j twice a day, every day
Trial: NCT01243697
Drug: desogestrel
RxNorm normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets of 75 µg, once daily during 112 days
Trial: NCT02914691
Drug: Dapagliflozine 10 mg once daily tablet treatment
RxNorm normalized name: lisinopril
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04066790
Drug: Pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib 400 mg taken orally everyday, every 3 weeks, for 4 cycles.
Trial: NCT04066790
Drug: nab-Paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel 100mg/m2 by intravenous (IV) infusion on day1, day8 and day15, every 3 weeks, for 4 cycles.
Trial: NCT04066790
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 9, followed by 6 mg/kg for remaining cycles till completion of 1 year trastuzumab
Trial: NCT01895257
Drug: systemic chemotherapy LV5FU2
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy with modified LV5FU2 will be administered according to the following regimen.~Cycle 1 onwards:~Day 1 Hour 0: Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion Hour + 2: 5-FU bolus 400 mg/m2, IV bolus Hour + 2: 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion Day 14 End of cycle. To be repeated every 14 days until evidence of treatment failure.
Trial: NCT01270789
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide administered as once daily sc injection
Trial: NCT00657280
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: No one is blinded to the treatments.
Trial: NCT03327155
Drug: Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One tablet, containing 300mg of TDF and 200mg of FTC once daily with food.
Trial: NCT02860091
Drug: Ropivacaine infusion
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delivered via paravertebral nerve block catheter.
Trial: NCT04066790
Drug: EC chemotherapy
RxNorm normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks 4 cycles (Cycles 5-8)
Trial: NCT02905994
Drug: Volasertib
RxNorm normalized name: Volasertib
DrugBank: Volasertib (DB12062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polo-Like Kinase Inhibitor
Trial: NCT02905994
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard chemotherapy at dosage and schedule for 7+3 induction
Trial: NCT02905994
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy at dosage and schedule for 7+3 induction